Released Feb 25, 2021, after the close
10-K filed Feb 25, 2021, 56 days after period end · 0001564590-21-008878
Q4 2020 · 10-K
Revenue$1.04M$1.04M −78.2% vs Q4 2019−97.0% vs Q3 2020
Net Income-$39.42M-$39.42M N/M vs Q4 2019N/M vs Q3 2020
EPS Diluted-$1.11-$1.11 N/M vs Q4 2019N/M vs Q3 2020
Operating Incomederived-$39,642,000N/M
Operating Cash Flowderived-$25,269,000N/M
Free Cash Flowderived-$25,269,000N/M
Margins · derived
Operating margin-3822.8%−3221.0 pt vs Q4 2019
Net margin-3801.2%−3233.0 pt vs Q4 2019
What the release said
The release
Same quarter
| Metric | Q4 2020 | Q4 2019 | Q4 2018 | Q4 2017 |
|---|---|---|---|---|
| Revenue | $1.04M | $4.77M | $3.74M | $3.32M |
| Net Income | -$39.42M | -$27.08M | -$26.16M | -$3.01M |
| EPS Diluted | -$1.11 | -$0.99 | -$1.03 | -$160.00 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Assembly Biosciences, Inc. · CIK 1426800 · Engraved from SEC EDGAR